Phase III UNCOVER-3 trial post hoc analysis: Long-term ixekizumab in moderate-to-severe plaque PsO

Results from a post hoc analysis of the phase III UNCOVER-3 (NCT01646177) trial evaluating long-term treat-to-target outcomes with ixekizumab in 385 patients with moderate-to-severe plaque psoriasis (PsO) were published in the Journal of the American Academy of Dermatology by Armstrong et al. The analysis assessed the proportion of patients who met treat-to-target goals, including Psoriasis Area and Severity Index (PASI) ≤2, PASI ≤1, body surface area (BSA) ≤3%, and BSA ≤1%, at Week 12 through 5 years (Week 264). 

Key data: At Week 12, PASI ≤2 and PASI ≤1 responses were attained by 71.7% and 53.0% of patients, respectively; of these, 94.5% (95% confidence interval [CI], 91.1–98.0) and 84.1% (95% CI, 77.7–90.5), respectively, maintained responses through Week 264. At Week 12, 62.1% and 50.9% of patients had BSA ≤3% and BSA ≤1% responses, respectively; among responders, 97.7% (95% CI, 95.1–100) and 88.7% (95% CI, 82.9–94.5), respectively, maintained responses through Week 264. 

Key learning: In this post hoc analysis, patients with moderate-to-severe plaque PsO who met treat-to-target outcomes with ixekizumab at Week 12 maintained responses over 5 years, supporting the long-term efficacy of ixekizumab in this patient population.